Meihua Intl Medical Techsの空売り状況は、投資家がMeihua Intl Medical Techsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Meihua Intl Medical Techs (NASDAQ:MHUA) 株価情報, 空売り情報

Meihua Intl Medical Techs

Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

米国の小売業者ファイブ・ビロウ(Five Below）の株は、市場予想を上回る四半期決算を発表し、第1四半期の見通し予想を上回ることを受け、市場取引開始前の取引で株価が急上昇した。

なぜ、ファイブ・ビロウの株価が12%上昇しているのか；プレマーケットで変動している20銘柄

Meihua International Medical Technologies Co., Ltd. - Ordinary Shares

Meihua International Medical Technologies Co Ltd

<p>Financial giants have made a conspicuous bullish move on Marriott International. Our analysis of options history for Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 69% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $458,058, and 2 were calls, valued at $117,940.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $220.0 to $270.0 for Marriott International over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Marriott International stands at 169.86, with a total volume reaching 2,161.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Marriott International, situated within the strike price corridor from $220.0 to $270.0, throughout the last 30 days.</p>
<h3>Marriott International Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742580967_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MAR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$10.0</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$250.00</td>
<td>$92.1K</td>
<td align="right">41</td>
<td align="right">97</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.3</td>
<td>$16.9</td>
<td>$16.9</td>
<td>$240.00</td>
<td>$76.0K</td>
<td align="right">293</td>
<td align="right">46</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$4.9</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$225.00</td>
<td>$55.8K</td>
<td align="right">0</td>
<td align="right">119</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$230.00</td>
<td>$43.4K</td>
<td align="right">424</td>
<td align="right">607</td>
</tr>
<tr>
<td>MAR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$41.3</td>
<td>$38.0</td>
<td>$39.7</td>
<td>$270.00</td>
<td>$39.7K</td>
<td align="right">254</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Marriott International</h3>
<p>Marriott operates 1.7 million rooms across roughly 30 brands. At the end of 2024, luxury represented roughly 10% of total rooms, premium was 43%, select service was 45%, midscale was 1%, and other was 1%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 98% of total rooms as of Dec. 31, 2024. North America makes up 62% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.</p>
<p>After a thorough review of the options trading surrounding Marriott International, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Marriott International Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,903,989, the price of MAR is down by -3.07%, reaching $237.32.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>What The Experts Say On Marriott International</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $299.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Marriott International with a target price of $298.<br />
&#x2A; An analyst from Truist Securities has decided to maintain their Hold rating on Marriott International, which currently sits at a price target of $300. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Marriott International options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Market Whales and Their Recent Bets on MAR Options

<p>High-rolling investors have positioned themselves bearish on Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TLN often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Talen Energy. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 12% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $59,175, and 7 calls, totaling $817,165.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $250.0 for Talen Energy over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Talen Energy's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Talen Energy's whale activity within a strike price range from $160.0 to $250.0 in the last 30 days. </p>
<h3>Talen Energy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742580962_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$56.5</td>
<td>$53.1</td>
<td>$54.78</td>
<td>$175.00</td>
<td>$130.8K</td>
<td align="right">5</td>
<td align="right">387</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$56.5</td>
<td>$53.1</td>
<td>$54.8</td>
<td>$175.00</td>
<td>$130.8K</td>
<td align="right">5</td>
<td align="right">434</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$56.4</td>
<td>$53.2</td>
<td>$54.79</td>
<td>$175.00</td>
<td>$130.8K</td>
<td align="right">5</td>
<td align="right">484</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.0</td>
<td>$51.5</td>
<td>$53.27</td>
<td>$160.00</td>
<td>$127.2K</td>
<td align="right">625</td>
<td align="right">387</td>
</tr>
<tr>
<td>TLN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$55.0</td>
<td>$51.5</td>
<td>$53.29</td>
<td>$160.00</td>
<td>$127.2K</td>
<td align="right">625</td>
<td align="right">434</td>
</tr>
</tbody>
</table>
</p>
<h3>About Talen Energy</h3>
<p>Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.</p>
<p>In light of the recent options history for Talen Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Talen Energy</h3>
<ul>
<li>Trading volume stands at 335,512, with TLN's price up by 0.68%, positioned at $214.4.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 144 days.</li>
</ul>
<h3>Expert Opinions on Talen Energy</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $262.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Talen Energy, targeting a price of $282.<br />
&#x2A; An analyst from Morgan Stanley downgraded its action to Overweight with a price target of $243. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Talen Energy, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Market Whales and Their Recent Bets on TLN Options

<p>Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $184,200, and 5 were calls, valued at $169,689.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $340.0 for Alnylam Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Alnylam Pharmaceuticals's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340.0 in the last 30 days. </p>
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742580956_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$6.9</td>
<td>$6.3</td>
<td>$6.3</td>
<td>$270.00</td>
<td>$63.0K</td>
<td align="right">2</td>
<td align="right">114</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.1</td>
<td>$260.00</td>
<td>$61.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.0</td>
<td>$260.00</td>
<td>$60.2K</td>
<td align="right">0</td>
<td align="right">200</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$25.0</td>
<td>$22.3</td>
<td>$25.0</td>
<td>$250.00</td>
<td>$50.0K</td>
<td align="right">213</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.5</td>
<td>$3.3</td>
<td>$4.67</td>
<td>$280.00</td>
<td>$37.8K</td>
<td align="right">516</td>
<td align="right">154</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alnylam Pharmaceuticals</h3>
<p>Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.</p>
<p>After a thorough review of the options trading surrounding Alnylam Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Alnylam Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 2,074,477, the price of ALNY is up 11.54% at $282.8. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Alnylam Pharmaceuticals</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $328.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Scotiabank persists with their Sector Outperform rating on Alnylam Pharmaceuticals, maintaining a target price of $338.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Alnylam Pharmaceuticals, which currently sits at a price target of $390.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $325.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $310.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Alnylam Pharmaceuticals, targeting a price of $280. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alnylam Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


ALNY

Check Out What Whales Are Doing With ALNY

<p>Barclays  analyst John Coffey   maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Equal-Weight and raises the price target from $10 to $12.</p>


News

Price Target

Analyst Ratings

STNE

Barclays Maintains Equal-Weight on StoneCo, Raises Price Target to $12

<p>Barclays  analyst Tom O'Malley   maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and raises the price target from $110 to $115.</p>


Barclays Maintains Overweight on Micron Technology, Raises Price Target to $115

<p>Consumers will likely get a reprieve from the Trump Administration&#8217;s tariffs at least until the <a href="https://www.benzinga.com/25/03/44149833/trump-delays-ford-gm-stellantis-from-from-tariffs-on-mexico-canada-for-one-month">first week of April</a>. Still, the scattershot tariffs, combined with weakening economic data, seem to have spooked investors.</p>
<p>We won&#8217;t know what happens next for a while, but Mexico <a href="https://www.benzinga.com/news/25/03/44092335/trumps-tariffs-threaten-canada-mexico-china-and-american-wallets">continues to be a target</a> of the Administration&#8217;s tariff policies.</p>
<p>We&#8217;re already starting to see the effects of this on imports like vehicle parts, electronics and apparel. But the even bigger hit may land on food and beverages. Berries, cucumbers, tomatoes, peppers, avocados and many more perishables are all imported to the U.S. from Mexico at high rates, especially during the off-season.</p>
<p>Tariffs and uncertainty are already impacting these imports, and more will likely follow. Companies that rely on these imports will struggle to pass on the added costs to their customers.</p>
<p>Let&#8217;s take a look at four food stocks you&#8217;d be wise to avoid.</p>
<h2 class="wp-block-heading"><strong>Chipotle Mexican Grill Inc.</strong> </h2>
<p>Let&#8217;s start with the obvious one. <strong>Chipotle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NASDAQ">CMG</a>), whose stock has taken hits from multiple directions over the last few months. For starters, fears of an economic slowdown have shifted how Americans eat, and restaurant sales are beginning to sag as more people choose to eat at home. And now, the promise of tariffs on Mexico threatens to drive up prices for the casual fast-dining chain, which sources many crucial products from Mexico, especially its famous guacamole.</p>
<p><figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcx4_iWwYRKwRtJVxI0R_h-7vkMzPD-2Y-jY-z-6qiVyqiMneTBS_-ddOVRCiLp-GgBiCtx3YyIrdf7o_NvrpVNzJ5sNHKP9Z7fXXIgKesqmb5sKm1NpMsAdsXbSrtB4-vWRfMAqA?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure></p>
<p>Chipotle could see severe price increases on its menu items, which source many ingredients like lettuce, tomatoes, avocados, fresh peppers and spices from Mexico. And while Chipotle's margins are strong compared to competitors like Wendy's or Domino's, gross margins have declined for three consecutive quarters. The stock's valuation is pretty lofty as well, with a 42.7 price-to-earnings (P/E) ratio, 2.36 PEG ratio, and a 5.7 Price-to-Sales (P/S) rate. CMG's latest earnings release disappointed investors as the company matched EPS estimates but missed on revenue. Benzinga Edge gives the stock only a 28.28 score for Momentum and 16.29 for Value.</p>
<h2 class="wp-block-heading"><strong>Calavo Growers Inc.</strong> </h2>
<p>One of the largest growers of avocados in the world, <strong>Calavo Growers</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) would face significant pressure from Mexico tariffs. Calavo sells avocados, tomatoes and fresh papaya to grocery stores, food distributors, clubhouse wholesalers and food service industries. In a sector with already razor-thin margins, Calavo has limited ability to absorb price increases and also limited negotiating power with its clients, who also have thin margins, like grocery stores and wholesalers. </p>
<p><figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXf4CgppD4UCDFy-OLP1UK6Zoo1pwE_kEWSlYIEg3Sv6Tta0rwJcu6l80DFSzEMuo-tN3SDPM9roeEuYMNB0kE2zPKrydnLW2ATcb-HzNxxcM0PhfwoOsrySF_8OBXww71svyGPF?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure></p>
<p>Calavo recently broke a string of 12 consecutive quarters with negative net margins. Still, its valuation remains elevated as the stock trades at 30 times earnings, two times book value and 19.5 times free cash flow. It also grades poorly in two crucial Benzinga Edge metrics: 22.73 in Momentum and 35.38 in Growth. In its most recent earnings release on March 12, the company beat on EPS estimates but missed on revenue. Analysis of CVGW is sparse, with only one firm updating its view so far in 2025. Lake Street analyst Ben Klieve has maintained the stock at Buy but lowered his price target to $35 from $40.</p>
<h2 class="wp-block-heading"><strong>US Foods Holding Corp.</strong> </h2>
<p>Another fresh food distributor with consistent revenue and earnings declines recently is <strong>US Foods Holding Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>), which distributes perishable, non-perishable, and non-food products to restaurants, schools, hospitals, government offices and grocery stores. Customers can get fresh, frozen, or dry food delivered from 70 different locations. The firm lists over 250,000 establishments as clients. US Foods has better profit margins than Calavo, but it&#8217;s still in a very slender range. The company saw its net profit margin shrink in the most recent Q4 earnings release, which was the first margin decline in nearly two years.</p>
<p><figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfO8JwghAwbl-G6W1wyRtknHgo7u-cNJih9zo4EPIdm6fBkczpmpbeWxxNq9pKodml-sbbMQF7Fl_agiUQ2GPaEjVlbslLCuQWKVOOmJvPibajMxs3SCR75tSfk4kCD_9t1I0vj?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure></p>
<p>US Foods could suffer from tariffs and declining restaurant foot traffic in the coming months. USFD earnings have been evaporating for three straight quarters and its valuation has gotten stretched. The stock currently trades at 32.7 times earnings, and despite its margin growth, the company still lags behind competitors like Sysco and Mission Produce in turning revenue dollars into actual profit.</p>
<p>Benzinga Edge isn't too fond of the stock's short-term future either, with just a 29.24 Value score and 43.19 Growth score. Some analysts defended the stock in February with price target hikes despite a Q4 revenue. However, EPS and revenue projections for the Q1 report on May 8 are lower than in the three previous quarters.</p>
<h2 class="wp-block-heading"><strong>Fresh Del Monte Produce Inc. </strong></h2>
<p>Don't let the enticing dividend fool you &#8211; Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) could struggle in the coming months if tariffs take a bite out of the company's profits. Fresh Del Monte produces and distributes fresh fruit and vegetables, including pineapples, melons, avocados, bananas, non-tropical fruits and other prepared foods. However, alarm bells began to sound in February thanks to a disastrous Q4 earnings report, which saw the company miss EPS estimates by nearly 30% and revenue by almost 2%.</p>
<p><figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXf8D0roez_0diA0WBOEcZ8vW9dUoFGyGLNFFNctpfV8pr38sF3lRyYTChq_-uhOzGiBSjLDwVAj8kxZMVZCxQfBV-JUvdQ85aJqF1RVk985RfG83XFgqnqKWfJnYLuLJb34NXJj?key=t0qZDK9I7zAEqr3n0pxiRKSh" alt="" /></figure></p>
<p>Fresh Del Monte posted a 3.3% profit margin in the most recent quarter, which is stronger than food giants like Tyson Foods or Archer Daniels but still less attractive than smaller competitors like Cal-Maine Foods and Vital Farms. The stock trades at just 10 times forward earnings with a 0.34 Price-to-Sales (P/S) ratio, but Benzinga Edge has poor short-term views for FDP shares thanks to a 52.13 Quality score and a paltry 4.48 Growth score.</p>
<h2 class="wp-block-heading"><strong>Volatility Trading Seminar: How to Find Profit Opportunities in Today's Unstable Market</strong></h2>
<p>Markets are swinging wildly—huge moves, massive opportunities and narrow windows to act. On <strong>Sunday, March 23</strong>, at 1 PM ET, 35-year Wall Street veteran <strong>Matt Maley</strong> will reveal his exact volatility trading playbook that he's used to identify profit opportunities, sometimes as high as 100%–450% in the past month. Learn how he's executing real, high-probability setups in today's market. <a href="https://events2.benzinga.com/matt-maley-webinar-sunday-mar23-2025-registration">Register</a> now and reserve your seat.</p>
<p><em>Photo: Shutterstock</em></p>


Regulations

Opinion

Trading Ideas

CVGW

USFD

4 Food Stocks To Consider Dumping As Trump Tariffs On Mexico Loom

<p>Barclays  analyst Theresa Chen   maintains LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) with a Equal-Weight and raises the price target from $79 to $80.</p>


Barclays Maintains Equal-Weight on LandBridge, Raises Price Target to $80

<p>The space economy is seeing an influx of <a href="https://www.benzinga.com/general/space">investment and innovation</a>.</p>
<p><strong>Intuitive Machines</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) expects to release its fourth-quarter 2024 earnings on March 24 before the market opens. The robust top-line expansion of its lunar payload services and NASA contracts make it a prime stock in the growing space exploration space as well as the aerospace and defense sector.</p>
<p>Intuitive Machines&#8217; forward 12-month price-to-sales (P/S) of 3.17X is above the peer group average of 2.32x, reflecting a premium valuation. This implies that investors are paying a premium price relative to anticipated sales growth compared to peers.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44253929/space-etfs-rocked-by-intuitive-machines-lunar-mishap-is-there-a-safer-bet">Space ETFs Rocked By Intuitive Machines&#8217; Lunar Mishap — Is There A Safer Bet?</a></strong></p>
<p>That said, Intuitive Machines is a volatile stock, as understood from its high Beta of 1.31, per CNBC. Beta of 1 and above means the stock tends to move more reactive to developments than the market in in general. For interested investors seeking exposure to the sector but without much of the involved risks, ETFs provide diversified exposure to the sectors. </p>
<p>This article examines the central themes regarding Intuitive Machines and identifies pertinent <a href="https://www.benzinga.com/etfs">ETFs offering exposure to the space economy</a> and the aerospace and defense sector.</p>
<p>The business of Intutive Machines is based on lunar missions and sophisticated space technologies. The contracts of the company with NASA, such as being part of the IM-1, IM-2, and IM-3 lunar payload missions, reflect its promise in the commercial space segment.</p>
<h2 class="wp-block-heading"><strong>Pertinent ETFs</strong></h2>
<ul>
<li><strong>Procure Space ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>): Tracks the S-Network Space Index, including space-related companies including Intuitive Machines. It&#8217;s expense ratio is 0.94%.</li>
</ul>
<ul>
<li><strong>ARK Space Exploration &amp; Innovation ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>): Although it does not carry LUNR in its holdings, this fund actively invests in the companies pioneering space exploration and innovation, like <strong>Iridium Satellite</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) and <strong>Rocket Lab Usa Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>). It carries an expense ratio of 0.75%.</li>
</ul>
<ul>
<li><strong>iShares U.S. Aerospace &amp; Defense ETF </strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>): Follows the Dow Jones U.S. Aerospace &amp; Defense Index, and carries an expense ratio of 0.4%. ITA&#8217;s portfolio is significantly skewed toward well-known aerospace and defense companies, in contrast to space-focused funds that contain speculative stocks like LUNR, which has NASA and Near Space Network contracts. More than 40% of the fund&#8217;s total assets are held by its top three holdings, which are <strong>GE Aerospace</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), <strong>RTX Corp. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), and<strong> Lockheed Martin Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>). ITA has been able to perform well during market turbulence thanks to this defensive allocation.</li>
</ul>
<ul>
<li><strong>SPDR S&amp;P Aerospace &amp; Defense ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>): Follows the S&amp;P Aerospace &amp; Defense Select Industry Index, and has an expense ratio of 0.35%. Since LUNR has been growing its aerospace and defense contract business, there is a possibility of XAR including LUNR in its portfolio in one of its coming reallocations.</li>
</ul>
<p>With the space economy growing, Intuitive Machines&#8217; growth highlights the growing overlap of space exploration, defense, and cutting-edge technology. </p>
<p>With LUNR&#8217;s participation in lunar missions and advanced innovations, the firm is an appealing investment opportunity for investors. Nonetheless, due to its high valuation, investors would need to evaluate their risk tolerance and look at diversified ETF approaches that offer exposure to the general space and defense sectors. Through the use of ETFs, investors are able to ride this dynamic and fast-growing sector while controlling risk.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44424030/exclusive-volatility-will-likely-be-hanging-around-trueshares-ceo-on-rising-demand-for-buffer">EXCLUSIVE: &#8216;Volatility Will Likely Be Hanging Around&#8217; — TrueShares CEO On Rising Demand For Buffered ETFs</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Sector ETFs

SPACE

ETFs

ARKX

IBBQ

IRDM

iShares Dow Jones US Aerospace & Defense Index Fund

LUNR

RKLB

ROKT

These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy

<p>Barclays  analyst Theresa Chen   maintains Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) with a Equal-Weight and lowers the price target from $44 to $41.</p>


Barclays Maintains Equal-Weight on Kodiak Gas Services, Lowers Price Target to $41

SGLY

Singularity Future Technology Shares Resume Trade Following Circuit Breaker Halt

<p>Barclays  analyst George Wang   maintains Jabil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) with a Overweight and raises the price target from $179 to $184.</p>


Barclays Maintains Overweight on Jabil, Raises Price Target to $184

WIIM

ELAB

PMGC Holdings shares are trading higher after the company announced it has repurchased shares from existing shareholders.

<p><i><strong>Brookfield Infrastructure Partners L.P. has agreed to sell entities to ArcLight Capital Partners, LLC</strong></i></p>
<p>NGPL PipeCo LLC (PipeCo) today announced that Brookfield Infrastructure Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIP#NYSE">BIP</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BIP#TSX">BIP</a>) has agreed to sell entities that hold its entire 25.0% minority interest in NGPL Holdings LLC (NGPL Holdings), PipeCo's indirect parent company, to one or more funds controlled by ArcLight Capital Partners, LLC (ArcLight). Upon closing, ArcLight funds will hold a 62.5% interest in NGPL Holdings. Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) continues to operate PipeCo's pipeline assets and holds a 37.5% interest in NGPL Holdings. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.</p>


Asset Sales

TSX:BIP

Brookfield Infrastructure Partners L.P. Has Agreed To Sell Entities That Hold Its Entire 25% Minority Interest In NGPL Holdings To One Or More Funds Controlled By ArcLight Capital Partners; Kinder Morgan Continues To Operate PipeCo's Pipeline Assets And Holds A 37.5% Interest In NGPL; No Financial Terms Disclosed

BFRI

Biofrontera shares are trading lower after the company reported a FY24 revenue miss.

<p>Barclays  analyst Theresa Chen   maintains DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) with a Equal-Weight and lowers the price target from $112 to $107.</p>


Barclays Maintains Equal-Weight on DT Midstream, Lowers Price Target to $107

<p><strong>Elon Musk</strong> has made another explosive claim about government waste, alleging that the U.S. Treasury and other federal agencies operate &#8220;magic money computers&#8221; that can issue payments with little oversight. <a href="https://www.youtube.com/watch?v=BDREZmpkIz8">Speaking</a> on &#8220;Verdict with Ted Cruz&#8221; at the White House, Musk told Sen. <strong>Ted Cruz</strong> (R-TX) and co-host <strong>Ben Ferguson</strong> that his team had uncovered 14 such computers.</p>
<p>&#8220;They&#8217;re mostly at Treasury; some are at [Department of Health and Human Services]. There&#8217;s one or two at State, there&#8217;s some at [Department of Defense],&#8221; he said.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>this is your last chance to become an investor for $0.80 per share.</strong></a></strong></li>
<li><strong>This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv"><strong>Invest In It Before It Fulfills 800 Pre-Orders</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Billions in Payments with Little Oversight</h2>
<p>&#8220;They just send money out of nothing,&#8221; Musk said, alleging that these systems process trillions of dollars in government payments with errors that could be costing taxpayers billions.</p>
<p>Musk, who has been working closely with the federal government since <strong>Donald Trump</strong> returned to the presidency, claimed that government financial systems are in disarray, making it easy for <a href="https://www.benzinga.com/personal-finance/25/03/44328962/1-9-billion-federal-scam-2-trillion-in-federal-waste-the-latest-findings-from-doge-as-elon-musk-says-money-is-poorly-spent">waste and fraud to thrive</a>.&nbsp;</p>
<p>&#8220;Okay, so, you may think like the government computers all talk to each other, they synchronize, they add up what funds are going somewhere and that they're coherent and that the numbers, for example, that you&#8217;re presented as a senator are actually the real numbers,&#8221; he said. &#8220;They're not. I mean, they're not totally wrong, but they're probably off by 5% or 10% in some cases.&#8221;</p>
<p>He continued, &#8220;I call a magic money computer any computer which can just make money out of thin air. It just issues payments.&#8221;</p>
<p><strong>Trending: Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel"><strong>and You Can Own a Piece of it From $0.55/Share</strong></a></strong></p>
<h2 class="wp-block-heading">Unchecked Spending and Massive Waste</h2>
<p>Musk also said nearly every federal agency is overspending on software licenses, media subscriptions, and credit cards. Some departments pay for software no one has ever logged into, while others have double the number of government credit cards compared to actual staff members. &#8220;I still don't have a good explanation for why this is the case,&#8221; Musk admitted.</p>
<p>The billionaire estimated that 80% of the problem is waste, with 20% being outright fraud. One example he highlighted was $1.9 billion allegedly given to a nonprofit linked to <strong>Stacey Abrams</strong>, a voting rights activist and two-time Georgia Democratic gubernatorial candidate. The money was meant for environmental projects, but Musk said the organization has only provided about 100 appliances so far. &#8220;Very expensive toaster,&#8221; he quipped.</p>
<p>Musk also pointed to cases where the government allegedly kept making payments to contractors even after contracts were supposed to be canceled. &#8220;Someone forgot to shut off the contract, and the company just kept getting money,&#8221; he said. He asked the hosts if that was waste or fraud, to which they replied, &#8220;Both.&#8221;</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it"><strong><em>Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">&#8216;Extreme Prosperity&#8217; or &#8216;Killer Robots&#8217;?</h2>
<p>In the interview, Musk also touched on the future of artificial intelligence, predicting that within 10 years, <a href="https://www.benzinga.com/news/24/03/37641748/elon-musk-foresees-ai-surpassing-human-intelligence-by-next-year-entire-humanity-by-2029">AI will be smarter than any human</a>. He also estimated that 50% of all miles driven will be autonomous within five years, increasing to 90% within a decade.</p>
<p>When asked about &#8220;killer robots annihilating humanity,&#8221; Musk said there&#8217;s a 10% to 20% chance AI could pose an <a href="https://www.benzinga.com/personal-finance/24/10/41196355/ai-will-do-most-jobs-better-faster-cheaper-silicon-valley-billionaire-vinod-khosla-calls-for-uni">existential threat to humanity</a> within the next 10 years. But he also believes that AI and robotics will make goods and services nearly free, so people won't be lacking anything—they'll just have to figure out how to find meaning in life.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"><strong> </strong><strong>and you can be a part of it for $0.18 per share</strong></a></strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>


'We've Found 14 Magic Money Computers,' Elon Musk Claims—'They Just Send Money Out Of Nothing'

IMRX

Immuneering shares are trading higher. Needham reiterated a Buy rating on the stock.

<p>Barclays  analyst Andrew Lazar   maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Equal-Weight and lowers the price target from $65 to $60.</p>


Barclays Maintains Equal-Weight on General Mills, Lowers Price Target to $60

<p>During the last three months, 5 analysts shared their evaluations of Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.8, a high estimate of $27.00, and a low estimate of $19.00. This current average represents a 4.2% decrease from the previous average price target of $23.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742580069_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Plymouth Industrial REIT. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitch Germain</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Plymouth Industrial REIT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Plymouth Industrial REIT compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Plymouth Industrial REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Plymouth Industrial REIT's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PLYM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Plymouth Industrial REIT analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Plymouth Industrial REIT</h2>
<p>Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.</p>
<h3>Plymouth Industrial REIT: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Plymouth Industrial REIT's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-6.33%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>307.36%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Plymouth Industrial REIT's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>28.78%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Plymouth Industrial REIT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.21%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.11</strong>, Plymouth Industrial REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLYM

Deep Dive Into Plymouth Industrial REIT Stock: Analyst Perspectives (5 Ratings)

<p>During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Y-mAbs Therapeutics, presenting an average target of $14.2, a high estimate of $22.00, and a low estimate of $7.00. This current average represents a 21.11% decrease from the previous average price target of $18.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742580060_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Y-mAbs Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alec Stranahan</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Y-mAbs Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Y-mAbs Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Y-mAbs Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Y-mAbs Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/YMAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Y-mAbs Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Y-mAbs Therapeutics</h2>
<p>Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.</p>
<h3>Understanding the Numbers: Y-mAbs Therapeutics's Finances</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Y-mAbs Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>13.41%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Y-mAbs Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of <strong>-25.63%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Y-mAbs Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-7.36%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-5.64%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, Y-mAbs Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


YMAB

Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views

Press Releases

Presenting on the Emerging Growth Conference 70 Day 2 on May 9 Register Now

Meihua International Medical Technologies Co., Ltd. to Present at the Sidoti Small Cap Conference and Update Investors at the Emerging Growth Conference on June 13, 2024

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

Events

Sidoti Events, LLC's Virtual June Small-Cap Conference

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million

Meihua International Medical Technologies Facilitates World's Second* 5G Remote Robot-Assisted Lobectomy

Meihua International Medical Technologies Co., Ltd. to Present at LIVE! with Webull Corporate Connect: Virtual Healthcare Investment Webinar on August 28, 2024

Comments

Meihua Intl Medical Techs

空売り

Meihua Intl Medical Techs (NASDAQ:MHUA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル